Showing results (71-80 of 78) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Biorxiv : the Preprint Server for Biology|February 6, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy targetZhiwei Ang, Annette Castro, Luca Paruzzo, et al.Nature|November 5, 2020
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cellsJaewoong Lee, Mark E Robinson, Ning Ma, et al.Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.Biorxiv : the Preprint Server for Biology|January 27, 2025
Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade gliomaPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.Nature Communications|April 28, 2022
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cellsTianyu Cai, Agnès Gouble, Kathryn L Black, et al.Cancer Discovery|October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyElena Sotillo, David M Barrett, Kathryn L Black, et al.Biorxiv : the Preprint Server for Biology|August 16, 2024
Characterization of aberrant splicing in pediatric central nervous system tumors reveals <i>CLK1</i> as a candidate oncogenic dependencyAmmar S Naqvi, Ryan J Corbett, Priyanka Seghal, et al.Neuro-Oncology Pediatrics|March 30, 2026
Alternative splicing in pediatric central nervous system tumors highlights oncofetal candidate <i>CLK1</i> exon 4Ammar S Naqvi, Patricia J Sullivan, Ryan J Corbett, et al.Pageof 8